These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 30370041)
1. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data. Kyriakou A; Trigoni A; Galanis N; Sotiriadis D; Patsatsi A Dermatol Reports; 2018 Oct; 10(2):7859. PubMed ID: 30370041 [TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar. Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078 [TBL] [Abstract][Full Text] [Related]
3. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295 [TBL] [Abstract][Full Text] [Related]
4. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436 [TBL] [Abstract][Full Text] [Related]
5. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335 [TBL] [Abstract][Full Text] [Related]
6. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040 [TBL] [Abstract][Full Text] [Related]
7. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156 [TBL] [Abstract][Full Text] [Related]
8. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938 [TBL] [Abstract][Full Text] [Related]